VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib

BACKGROUND: Currently, sunitinib represents one of the therapeutic strongholds for renal cell carcinoma, but the criteria for treatment selection are lacking. We assessed the role of vascular endothelial growth factor (VEGF) and VEGF receptor (VEGFR) polymorphisms in the prediction of the clinical o...

Descripción completa

Detalles Bibliográficos
Autores principales: Scartozzi, M, Bianconi, M, Faloppi, L, Loretelli, C, Bittoni, A, Del Prete, M, Giampieri, R, Maccaroni, E, Nicoletti, S, Burattini, L, Minardi, D, Muzzonigro, G, Montironi, R, Cascinu, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3619056/
https://www.ncbi.nlm.nih.gov/pubmed/23511629
http://dx.doi.org/10.1038/bjc.2012.501

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3619056/
https://www.ncbi.nlm.nih.gov/pubmed/23511629
http://dx.doi.org/10.1038/bjc.2012.501

Ejemplares similares